Pharma's Almanac

Financial constraints and regulatory uncertainties are the two primary challenges facing drug developers in the cell and gene therapy sector. Hear from Jimmy Vanhove, CEO of Viralgen Vector Core, about how partnering with a CDMO can significantly improve process economics and ensure commercial viability. Read more: https://lnkd.in/eEkrb6dq #Biotech #Celltherapy #Genetherapy #Partnerships

#FDA Approves 9 Bispecific Antibodies – What’s Next in #Biopharma? Bispecific antibodies are revolutionizing treatment with their enhanced efficacy and precise, dual-targeting capabilities. #Biotech #Antibody

In this very illuminating new article from our friends at Wheeler Bio, Inc., they discuss how, as the industry embraces Pharma 4.0, the convergence of digitalization, automation, and strategic collaboration promises to shape the future of biopharmaceutical innovation and manufacturing. #biopharma #cdmo #pharma40 #biomanufacturing #digitalization #automation #mabs #artificialintelligence

The microbiome could be the key to optimizing immuno-oncology therapies, but expertise in developing and manufacturing live biotherapeutics is crucial. Stacy Burns-Guydish, President at List Biological Laboratories, Inc., shares insights on the challenges and innovations in microbiome development. Read more: https://lnkd.in/eNMRnae5 #Innovation #Biotech #Microbiome #Immunooncology

New on Pharma's Almanac: Mikart, LLC’s Gus LaBella explains how demand for liquid suspension product development and manufacturing is increasing as more drug companies seek to provide tailored products for pediatric and geriatric patients. #pharma #cdmo #formulation #api #pediatric #liquidsuspension

In this Q1 installment of the Pharma's Almanac roundtable, we asked industry experts how #pharma and #biopharma companies can demonstrate their commitment to #ESG principles in manufacturing. View the roundtable here: https://lnkd.in/gTZCHsYf Our expert panel included contributors from BIOVECTRA, Evonik, GBI Bio, Hamilton Company, Lonza, Mikart, LLC, Olon, Oxford Biomedica, PCI Pharma Services, Samsung Biologics, TriRx Pharmaceutical Services, LLC, Wheeler Bio, Inc., 3PBIOVIAN, Agilent Technologies, Astrea Bioseparations, BASF, BioCina, BIOSENIC S.A., Bormioli Pharma, Charles River Laboratories, C2 PHARMA, Cellares, Core Biogenesis, Cytiva, IGC PHARMA, FourPlus Immersive, Likarda, Navin Molecular, OrganoBiotech, Inc., ScaleReady, Sterling Pharma Solutions, Thermo Fisher Scientific, TrakCel, and WuXi Biologics

New on Pharma's Almanac: Samsung Biologics' JC Ryan Lee discusses how a CDMO can become a trusted partner to its clients to help fulfill their commitment to patients. #cdmo #strategicpartnership #trust #biopharma #biologics #biomanufacturing

New on Pharma's Almanac: Cell X Technologies’ Karen Weisinger explains the promise organoids offer to transform activities ranging regenerative medicine to drug discovery and process development and how Cell X’s Celligent platform can help realize that promise. #biopharma #celltherapy #organoids #automation #ipscs #platformtechnology

New on Pharma's Almanac Corning Pharmaceutical Technologies’ Jessica Buday helps us explore Corning® Viridian® Vials, a new sustainable high-performance alternative for pharmaceutical packaging. #pharma #parenterals #packaging #vials #sustainability #fillfinish #biopharma

In another illuminating Q&A from earlier in 2024, PCI Pharma Services' Jerome Detreille, Derek Truninger, and Peter Kim discuss the how robotic sterile fill-finish services can help accelerate the production of clinical trials materials. #pharma #cdmo #fillfinish #automation #sterile #clinicaltrials #clinicalmanufacturing